Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use.
This regulatory decision makes IGALMI the first FDA-approved treatment that adults can use at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
IGALMI (dexmedetomidine) sublingual film is a prescription medicine that is placed under the tongue or between the lower lip and gum and is used for the treatment of sudden (acute) agitation in adults with schizophrenia, schizoaffective disorder, or bipolar disorder I or II.
Read Also: Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030
Phase 3 Trial Confirms Consistent Tolerability
During the 12-week Phase 3 SERENITY At-Home Safety and Tolerability Trial, investigators treated 1,160 agitation episodes across 102 patients with IGALMI.
Patients maintained consistent tolerability…